Ronit Gavrieli

Ronit Gavrieli

Auto-generated profile, based on publicly available information

Ronit Gavrieli

Division of Pediatrics, Pediatric Hematology Clinic, Kfar Saba, Israel

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 November 2018 in European Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
BWBaruch Wolach
Baruch Wolach
RGRonit Gavrieli
Ronit Gavrieli
OWOfir Wolach
Ofir Wolach
TSTal Stauber
Tal Stauber
OAOmar Abuzaitoun
Omar Abuzaitoun
AEAmos Etzioni
Amos Etzioni

24 November 2020 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
ALAtar Lev
Atar Lev
YLYu Nee Lee
Yu Nee Lee
GSGuangping Sun
Guangping Sun
EHEnas Hallumi
Enas Hallumi
ASAmos J. Simon
Amos J. Simon
RSRaz Somech
Raz Somech
The T cell receptor (TCR) signaling pathway is an ensemble of numerous proteins that are crucial for an adequate immune response. Disruption of any protein involved in this pathway leads to severe immunodeficiency and unfavorable clinical outcomes. Here, we describe an infant with severe immunodeficiency who was found to have novel biallelic mutations in SLP76. SLP76 is a key protein involved in TCR signaling and in other hematopoietic pathways. Previous studies of this protein were performed using Jurkat-derived human leukemic T cell lines and SLP76-deficient mice. Our current study links this gene, for the first time, to a human immunodeficiency characterized by early-onset life-threatening infections, combined T and B cell immunodeficiency, severe neutrophil defects, and impaired platelet aggregation. Hereby, we characterized aspects of the patient's immune phenotype, modeled them with an SLP76-deficient Jurkat-derived T cell line, and rescued some consequences using ectopic expression of wild-type SLP76. Understanding human diseases due to SLP76 deficiency is helpful in explaining the mixed T cell and neutrophil defects, providing a guide for exploring human SLP76 biology.

7 June 2020 in Clinical and Experimental Immunology
Verified
Journal Article
Closed access
PDF file
TBTal Barkai
Tal Barkai
RSRaz Somech
Raz Somech
ABArnon Broides
Arnon Broides
RGRonit Gavrieli
Ronit Gavrieli
BWBaruch Wolach
Baruch Wolach
TSTali Stauber
Tali Stauber

19 September 2024 in Blood
Verified
Journal Article
Closed access
BWBaruch Wolach
Baruch Wolach
RGRonit Gavrieli
Ronit Gavrieli
OWOfir Wolach
Ofir Wolach
PSPazit Salamon
Pazit Salamon
MBMartin de Boer
Martin de Boer
IRIdit Lachover Roth
Idit Lachover Roth
Neutrophils are the first line of defense against invading pathogens. Neutrophils execute and modulate immune responses by generating reactive oxygen species (ROS). Chronic granulomatous disease (CGD) is a primary immune deficiency disorder of phagocytes, caused by inherited mutations in the genes of the nicotinamide adenine dinucleotide phosphate reduced oxidase enzyme. These mutations lead to failure of ROS generation followed by recurrent bacterial and fungal infections, frequently associated with hyperinflammatory manifestations. We report a multicenter cumulative experience in diagnosing and treating patients with CGD. From 1986 to 2021, 2918 patients experiencing frequent infections were referred for neutrophil evaluation. Among them, 110 patients were diagnosed with CGD: 56 of Jewish ancestry, 48 of Arabic ancestry, and 6 of non-Jewish/non-Arabic ancestry. As opposed to other Western countries, the autosomal recessive (AR) CGD subtypes were predominant in Israel (71/110 patients). Thirty-nine patients had X-linked CGD, in most patients associated with severe infections (clinical severity score ≥3) and poor outcomes, presenting at a significantly earlier age than AR-CGD subtypes. The full spectrum of infections and hyperinflammatory manifestations is described. Six patients had hypomorphic mutations with significantly milder phenotype, clinical severity score ≤2, and better outcomes. Hematopoietic stem cell transplantation was implemented in 39 of 110 patients (35.5%). Successful engraftment was achieved in 92%, with 82% long-term survival and 71% full clinical recovery. CGD is a complex disorder requiring a multiprofessional team. Early identification of the genetic mutation is essential for prompt diagnosis, suitable management, and prevention.

21 May 2011 in Journal of Clinical Immunology
Verified
Journal Article
Closed access
PDF file
BWBaruch Wolach
Baruch Wolach
ABArnon Broides
Arnon Broides
TZTal Zeeli
Tal Zeeli
RGRonit Gavrieli
Ronit Gavrieli
MBMartin de Boer
Martin de Boer
DRDirk Roos
Dirk Roos